Dapsone gel, 5% — Competitive Intelligence Brief

Dapsone gel, 5% (Dapsone gel, 5%) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfone antimicrobial and anti-inflammatory agent. Area: Dermatology.

marketed Sulfone antimicrobial and anti-inflammatory agent Dihydrofolate reductase; neutrophil function modulation Dermatology Small molecule

Target snapshot

Dapsone gel, 5% (Dapsone gel, 5%) — Vanderbilt University Medical Center. Dapsone is a sulfone antimicrobial and anti-inflammatory agent that inhibits bacterial dihydrofolate reductase and suppresses neutrophil function and reactive oxygen species production.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dapsone gel, 5% TARGET	Dapsone gel, 5%	Vanderbilt University Medical Center	marketed	Sulfone antimicrobial and anti-inflammatory agent	Dihydrofolate reductase; neutrophil function modulation
Dapsone Topical Gel + vehicle control	Dapsone Topical Gel + vehicle control	Allergan	phase 3	Sulfone antimicrobial and anti-inflammatory agent	Dihydropteroate synthase; neutrophil function modulation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfone antimicrobial and anti-inflammatory agent class)

1. Allergan · 1 drug in this class
2. Vanderbilt University Medical Center · 1 drug in this class